Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Despite recent advances in the treatment of NSCLC overall survival within these patients
remains dismal and there is yet an unmet medical need for additional treatment options. In
this phase II study a combination of chemotherapy with an antibody (cisplatin, docetaxel and
bevacizumab) is tested to determine the objective response rate in patients with unresectable
and advanced non-small cell lung cancer. This response rate will be compared with historical
data.